Zealand Pharma A/S, of Copenhagen, Denmark, reported royalty revenues of DKK6.6 million (US$1.25 million) from partner Sanofi SA, of Paris, from global 2013 sales of Lyxumia (lixisenatide), a Zealand-discovered GLP-1 receptor agonist to treat type 2 diabetes.